Trial Profile
Radionuclide therapy using 177Lu-PSMA: extension of a pilot study in men with castrate-resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LuPin; LuPIN-1
- 01 Feb 2023 Results (n=32) assessing response rates and efficacy using predictive tools in a sub-group of men with SPECT TTV progression published in the Journal of Nuclear Medicine
- 01 Jan 2023 Results of LuPin substudy published in the Journal of Nuclear Medicine
- 01 Apr 2022 Results published in the Journal of Nuclear Medicine